Discovery ofN-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

Citations Over TimeTop 10% of 2007 papers

Abstract

In our continued efforts to search for potent and novel receptor tyrosine kinase (RTK) inhibitors as potential anticancer agents, we discovered, through a structure-based design, that 3-aminoindazole could serve as an efficient hinge-binding template for kinase inhibitors. By incorporating an N,N'-diaryl urea moiety at the C4-position of 3-aminodazole, a series of RTK inhibitors were generated, which potently inhibited the tyrosine kinase activity of the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor families. A number of compounds with potent oral activity were identified by utilizing an estradiol-induced mouse uterine edema model and an HT1080 human fibrosarcoma xenograft tumor model. In particular, compound 17p (ABT-869) was found to possess favorable pharmacokinetic profiles across different species and display significant tumor growth inhibition in multiple preclinical animal models.

Related Papers

• → TNP‐470 Suppresses the Tumorigenicity of HT1080 Fibrosarcoma TumorThrough the Inhibition of VEGF Secretion From the Tumor Cells(2001)11 cited
• → In vitro decreases of the fibrinolytic potential of cultured human fibrosarcoma cell line, HT1080, by Nigella sativa oil(2004)44 cited
• → DNA aptamer S11e recognizes fibrosarcoma and acts as a tumor suppressor(2021)17 cited
• → Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity(2017)6 cited
• [Effect of tissue factor in extravascular migration of fibrosarcoma cells].(2011)